Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1995-05

AUTHORS

Per Lenner, Joakim Dillner, Fredrik Wiklund, Göran Hallmans, Ulf Stendahl

ABSTRACT

To investigate whether the serum antibody responses to human papillomavirus (HPV) in cervical carcinoma were related to the clinical and histopathological features of the tumors and how the antibody responses were affected by treatment, pretreatment serum samples from 66 patients with carcinoma of the cervix were studied for the presence of IgA or IgG responses against six defined HPV epitopes. Posttreatment serum samples were drawn from the same patients 2–24 months after initiation of treatment. There was no significant correlation between pretreatment level of any of the investigated antibodies and clinical stage or differentiation of tumor. For the IgA responses to the epitopes 245∶16 and 245∶18 in the E2 protein there was a significant correlation between an increased pretreatment antibody level and a shortened survival. A high pretreatment value of IgA against 245∶16 was also associated with the absence of any complete response after therapy. The antibody levels declined dramatically after therapy for most of the antigens studied. However, this decline was seen both among the 53 patients with complete remission and among the 13 patients with remaining or progressive disease. Thus, the investigated serological responses were not useful as tumor markers, since patients with progressive, latestage disease may fail to mount an antibody response to these proteins. However, pretreatment levels of the serological responses to the HPV epitopes 245∶16 and 245∶18 were associated with prognosis in cervical cancer. More... »

PAGES

201-205

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01517352

DOI

http://dx.doi.org/10.1007/bf01517352

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021497132

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7728779


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Papillomaviridae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Papillomavirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Virus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uterine Cervical Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Oncology, University of Ume\u00e5, S-901 85, Umea, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.12650.30", 
          "name": [
            "Department of Oncology, University of Ume\u00e5, S-901 85, Umea, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lenner", 
        "givenName": "Per", 
        "id": "sg:person.0721051037.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721051037.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dillner", 
        "givenName": "Joakim", 
        "id": "sg:person.01254603055.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254603055.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, University of Ume\u00e5, S-901 85, Umea, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.12650.30", 
          "name": [
            "Department of Oncology, University of Ume\u00e5, S-901 85, Umea, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wiklund", 
        "givenName": "Fredrik", 
        "id": "sg:person.0620136570.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620136570.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, University of Ume\u00e5, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.12650.30", 
          "name": [
            "Department of Pathology, University of Ume\u00e5, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hallmans", 
        "givenName": "G\u00f6ran", 
        "id": "sg:person.01023564410.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023564410.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gynecological Oncology, University of Ume\u00e5, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.12650.30", 
          "name": [
            "Department of Gynecological Oncology, University of Ume\u00e5, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stendahl", 
        "givenName": "Ulf", 
        "id": "sg:person.01337602670.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337602670.67"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1995-05", 
    "datePublishedReg": "1995-05-01", 
    "description": "To investigate whether the serum antibody responses to human papillomavirus (HPV) in cervical carcinoma were related to the clinical and histopathological features of the tumors and how the antibody responses were affected by treatment, pretreatment serum samples from 66 patients with carcinoma of the cervix were studied for the presence of IgA or IgG responses against six defined HPV epitopes. Posttreatment serum samples were drawn from the same patients 2\u201324 months after initiation of treatment. There was no significant correlation between pretreatment level of any of the investigated antibodies and clinical stage or differentiation of tumor. For the IgA responses to the epitopes 245\u223616 and 245\u223618 in the E2 protein there was a significant correlation between an increased pretreatment antibody level and a shortened survival. A high pretreatment value of IgA against 245\u223616 was also associated with the absence of any complete response after therapy. The antibody levels declined dramatically after therapy for most of the antigens studied. However, this decline was seen both among the 53 patients with complete remission and among the 13 patients with remaining or progressive disease. Thus, the investigated serological responses were not useful as tumor markers, since patients with progressive, latestage disease may fail to mount an antibody response to these proteins. However, pretreatment levels of the serological responses to the HPV epitopes 245\u223616 and 245\u223618 were associated with prognosis in cervical cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01517352", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "human papillomavirus", 
      "antibody levels", 
      "antibody response", 
      "serum antibodies", 
      "serological response", 
      "pretreatment levels", 
      "serum samples", 
      "posttreatment serum samples", 
      "high pretreatment values", 
      "presence of IgA", 
      "initiation of treatment", 
      "pretreatment serum samples", 
      "differentiation of tumor", 
      "significant correlation", 
      "complete remission", 
      "IgA responses", 
      "progressive disease", 
      "complete response", 
      "histopathological features", 
      "IgG responses", 
      "tumor characteristics", 
      "uterine cervix", 
      "Patient 2", 
      "clinical stage", 
      "cervical cancer", 
      "cervical carcinoma", 
      "pretreatment values", 
      "HPV epitopes", 
      "tumor markers", 
      "patients", 
      "carcinoma", 
      "antibodies", 
      "cervix", 
      "papillomavirus", 
      "IgA", 
      "therapy", 
      "tumors", 
      "E2 protein", 
      "treatment", 
      "disease", 
      "survival", 
      "epitopes", 
      "response", 
      "remission", 
      "prognosis", 
      "levels", 
      "cancer", 
      "antigen", 
      "months", 
      "protein", 
      "markers", 
      "correlation", 
      "initiation", 
      "differentiation", 
      "samples", 
      "absence", 
      "decline", 
      "presence", 
      "stage", 
      "features", 
      "characteristics", 
      "values", 
      "relation"
    ], 
    "name": "Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix", 
    "pagination": "201-205", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021497132"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01517352"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7728779"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01517352", 
      "https://app.dimensions.ai/details/publication/pub.1021497132"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_277.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01517352"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01517352'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01517352'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01517352'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01517352'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      20 PREDICATES      106 URIs      97 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01517352 schema:about N052bec11ea054902ab86ca69f5b246ad
2 N089f51638751490aadf9977ff7876f40
3 N0abeda09ba2c44e8bfc66bc96a0fc938
4 N18f0976cba044aefbef7a1b90f14f9cf
5 N1d304f40316b42a0b99fdd954ce45690
6 N27e8a9cc36074e5d9e1c447129209530
7 N2c24ea9df8094a4aa4fd2c131f1ad7df
8 N301c7f6d817c4044a5f09afc1bddf1ea
9 N3c2b2c4061de47999f7e08a556b3b5a8
10 Nab18286ffea140bc8e6b83bc5bab0ce4
11 Nad36387c3dd14b05a33e9e3895d2fc96
12 Nae8909420d69468da5d85046db44faa9
13 Nb8d5a2fc239d4a65901cf0c9ed556470
14 Nc7d600fde8f7430d82823a05403eef53
15 Nfa9ec19c51d6432f86af378400ccaba6
16 Nff3b03b43ee1449385a0823060994aff
17 anzsrc-for:11
18 anzsrc-for:1107
19 anzsrc-for:1112
20 schema:author Nbe8f131adf8642838ea067259ab543e0
21 schema:datePublished 1995-05
22 schema:datePublishedReg 1995-05-01
23 schema:description To investigate whether the serum antibody responses to human papillomavirus (HPV) in cervical carcinoma were related to the clinical and histopathological features of the tumors and how the antibody responses were affected by treatment, pretreatment serum samples from 66 patients with carcinoma of the cervix were studied for the presence of IgA or IgG responses against six defined HPV epitopes. Posttreatment serum samples were drawn from the same patients 2–24 months after initiation of treatment. There was no significant correlation between pretreatment level of any of the investigated antibodies and clinical stage or differentiation of tumor. For the IgA responses to the epitopes 245∶16 and 245∶18 in the E2 protein there was a significant correlation between an increased pretreatment antibody level and a shortened survival. A high pretreatment value of IgA against 245∶16 was also associated with the absence of any complete response after therapy. The antibody levels declined dramatically after therapy for most of the antigens studied. However, this decline was seen both among the 53 patients with complete remission and among the 13 patients with remaining or progressive disease. Thus, the investigated serological responses were not useful as tumor markers, since patients with progressive, latestage disease may fail to mount an antibody response to these proteins. However, pretreatment levels of the serological responses to the HPV epitopes 245∶16 and 245∶18 were associated with prognosis in cervical cancer.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N2c6f9557825940c784cca3398e0d71cf
27 N3fef7bb0715a427abd75445ebf6d600a
28 sg:journal.1096240
29 schema:keywords E2 protein
30 HPV epitopes
31 IgA
32 IgA responses
33 IgG responses
34 Patient 2
35 absence
36 antibodies
37 antibody levels
38 antibody response
39 antigen
40 cancer
41 carcinoma
42 cervical cancer
43 cervical carcinoma
44 cervix
45 characteristics
46 clinical stage
47 complete remission
48 complete response
49 correlation
50 decline
51 differentiation
52 differentiation of tumor
53 disease
54 epitopes
55 features
56 high pretreatment values
57 histopathological features
58 human papillomavirus
59 initiation
60 initiation of treatment
61 levels
62 markers
63 months
64 papillomavirus
65 patients
66 posttreatment serum samples
67 presence
68 presence of IgA
69 pretreatment levels
70 pretreatment serum samples
71 pretreatment values
72 prognosis
73 progressive disease
74 protein
75 relation
76 remission
77 response
78 samples
79 serological response
80 serum antibodies
81 serum samples
82 significant correlation
83 stage
84 survival
85 therapy
86 treatment
87 tumor characteristics
88 tumor markers
89 tumors
90 uterine cervix
91 values
92 schema:name Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix
93 schema:pagination 201-205
94 schema:productId N930c5adb45d443ce8d86dc6b4540e0e1
95 Ncb37ec0464684da1937ca040a9f9fd09
96 Nd96c4594b443495485a91e885ce2e873
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021497132
98 https://doi.org/10.1007/bf01517352
99 schema:sdDatePublished 2022-09-02T15:48
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N5a2e79c47edb476db6d6a6ebe9beb85e
102 schema:url https://doi.org/10.1007/bf01517352
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N052bec11ea054902ab86ca69f5b246ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Survival Rate
108 rdf:type schema:DefinedTerm
109 N089f51638751490aadf9977ff7876f40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Papillomaviridae
111 rdf:type schema:DefinedTerm
112 N0abeda09ba2c44e8bfc66bc96a0fc938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Antibodies, Viral
114 rdf:type schema:DefinedTerm
115 N18f0976cba044aefbef7a1b90f14f9cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Uterine Cervical Neoplasms
117 rdf:type schema:DefinedTerm
118 N1b010c4cb2464429ad2050598be63360 rdf:first sg:person.0620136570.19
119 rdf:rest N1ed31f22b1a442ffb0009cfaafbe646e
120 N1d304f40316b42a0b99fdd954ce45690 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Follow-Up Studies
122 rdf:type schema:DefinedTerm
123 N1ed31f22b1a442ffb0009cfaafbe646e rdf:first sg:person.01023564410.54
124 rdf:rest N9e5566910c244152b58b49323f9203dd
125 N27e8a9cc36074e5d9e1c447129209530 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adolescent
127 rdf:type schema:DefinedTerm
128 N2c24ea9df8094a4aa4fd2c131f1ad7df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Aged, 80 and over
130 rdf:type schema:DefinedTerm
131 N2c6f9557825940c784cca3398e0d71cf schema:issueNumber 3
132 rdf:type schema:PublicationIssue
133 N301c7f6d817c4044a5f09afc1bddf1ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Aged
135 rdf:type schema:DefinedTerm
136 N3c2b2c4061de47999f7e08a556b3b5a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 N3fef7bb0715a427abd75445ebf6d600a schema:volumeNumber 40
140 rdf:type schema:PublicationVolume
141 N5a2e79c47edb476db6d6a6ebe9beb85e schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N930c5adb45d443ce8d86dc6b4540e0e1 schema:name dimensions_id
144 schema:value pub.1021497132
145 rdf:type schema:PropertyValue
146 N9e5566910c244152b58b49323f9203dd rdf:first sg:person.01337602670.67
147 rdf:rest rdf:nil
148 Nab18286ffea140bc8e6b83bc5bab0ce4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 Nad36387c3dd14b05a33e9e3895d2fc96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Papillomavirus Infections
153 rdf:type schema:DefinedTerm
154 Nae8909420d69468da5d85046db44faa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Biomarkers, Tumor
156 rdf:type schema:DefinedTerm
157 Nb89dcbf9298146ae95c5fc519823d6dd rdf:first sg:person.01254603055.20
158 rdf:rest N1b010c4cb2464429ad2050598be63360
159 Nb8d5a2fc239d4a65901cf0c9ed556470 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Treatment Outcome
161 rdf:type schema:DefinedTerm
162 Nbe8f131adf8642838ea067259ab543e0 rdf:first sg:person.0721051037.52
163 rdf:rest Nb89dcbf9298146ae95c5fc519823d6dd
164 Nc7d600fde8f7430d82823a05403eef53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Adult
166 rdf:type schema:DefinedTerm
167 Ncb37ec0464684da1937ca040a9f9fd09 schema:name pubmed_id
168 schema:value 7728779
169 rdf:type schema:PropertyValue
170 Nd96c4594b443495485a91e885ce2e873 schema:name doi
171 schema:value 10.1007/bf01517352
172 rdf:type schema:PropertyValue
173 Nfa9ec19c51d6432f86af378400ccaba6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Tumor Virus Infections
175 rdf:type schema:DefinedTerm
176 Nff3b03b43ee1449385a0823060994aff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
183 schema:name Immunology
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
186 schema:name Oncology and Carcinogenesis
187 rdf:type schema:DefinedTerm
188 sg:journal.1096240 schema:issn 0340-7004
189 1432-0851
190 schema:name Cancer Immunology, Immunotherapy
191 schema:publisher Springer Nature
192 rdf:type schema:Periodical
193 sg:person.01023564410.54 schema:affiliation grid-institutes:grid.12650.30
194 schema:familyName Hallmans
195 schema:givenName Göran
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023564410.54
197 rdf:type schema:Person
198 sg:person.01254603055.20 schema:affiliation grid-institutes:grid.4714.6
199 schema:familyName Dillner
200 schema:givenName Joakim
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254603055.20
202 rdf:type schema:Person
203 sg:person.01337602670.67 schema:affiliation grid-institutes:grid.12650.30
204 schema:familyName Stendahl
205 schema:givenName Ulf
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337602670.67
207 rdf:type schema:Person
208 sg:person.0620136570.19 schema:affiliation grid-institutes:grid.12650.30
209 schema:familyName Wiklund
210 schema:givenName Fredrik
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620136570.19
212 rdf:type schema:Person
213 sg:person.0721051037.52 schema:affiliation grid-institutes:grid.12650.30
214 schema:familyName Lenner
215 schema:givenName Per
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721051037.52
217 rdf:type schema:Person
218 grid-institutes:grid.12650.30 schema:alternateName Department of Gynecological Oncology, University of Umeå, Sweden
219 Department of Oncology, University of Umeå, S-901 85, Umea, Sweden
220 Department of Pathology, University of Umeå, Sweden
221 schema:name Department of Gynecological Oncology, University of Umeå, Sweden
222 Department of Oncology, University of Umeå, S-901 85, Umea, Sweden
223 Department of Pathology, University of Umeå, Sweden
224 rdf:type schema:Organization
225 grid-institutes:grid.4714.6 schema:alternateName Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
226 schema:name Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...